Genetic test for Plavix use may be unneeded: study

December 29, 2011

A new study published Wednesday cast doubt on the usefulness of a genetic test for patients taking the anti-coagulant drug Plavix, calling into question last year's FDA warning about the blood thinner.

The study, a new review of 32 previous clinical studies published in the , said the genetic test may not help identify those patients more at risk of a heart attack or other cardiac event.

Plavix, one of the world's top selling drugs, is marketed by US-based Bristol-Myers Squibb and France's Sanofi. It reduces the risk of heart attack and stroke by keeping from sticking together to cause clots.

In 2010, the US Food and Drug Administraion ordered the manufacturers to add a boxed warning to Plavix packets saying the drug may be less effective in preventing heart attacks in people who cannot metabolize it properly.

The FDA said an estimated two to 14 percent of the US population are poor metabolizers who have a certain variant of the gene that makes the CYP2C19 , which converts Plavix to its active form.

The FDA had recommended that doctors prescribe higher doses of Plavix, or clopidogrel, to those patients who had the genetic test and were found not to produce enough of the enzyme.

But researchers led by Michael Holmes at University College London concluded after their new review of studies involving 42,000 patients that those with the did not have more than other patients.

"Despite associations between CYP2C19 genotype, clopidogrel metabolism, and platelet aggregation, this systematic review and meta-analysis does not demonstrate a clinically important association of genotype with ," researchers led by Michael Holmes at University College London said.

The only notable possible exception was in patients with stent thrombosis, they wrote.

"The FDA's warnings on Plavix were premature and were not based on solid science," said Steven Nissen, a cardiologist at the Cleveland Clinic Foundation, in an editorial published in the Journal of the AMA.

Plavix sales totalled $5.4 billion in the first three quarters of 2011, as compared with $4.9 billion in the same period last year.

About 40 million people take the drug worldwide.

Explore further: Analysis does not support genetic test before use of anti-clotting drug

Related Stories

Recommended for you

Researchers identify source of opioids' side effects

January 17, 2017

A commercially available drug may help drastically reduce two side effects of opioid painkillers—a growing tolerance and a paradoxical increased sensitivity to pain—without affecting the drugs' ability to reduce pain, ...

CVS generic competitor to EpiPen, sold at a 6th the price

January 12, 2017

CVS is now selling a rival, generic version of Mylan's EpiPen at about a sixth of its price, just months after the maker of the life-saving allergy treatment was eviscerated before Congress because of its soaring cost to ...

Many misuse OTC sleep aids: survey

December 29, 2016

(HealthDay)—People struggling with insomnia often turn to non-prescription sleep remedies that may be habit-forming and are only intended for short-term use, according to a new Consumer Reports survey.

The pill won't kill your sexual desire, researchers say

December 15, 2016

Taking the pill doesn't lower your sexual desire, contrary to popular belief, according to research published in the Journal of Sexual Medicine. The authors of the research, from the University of Kentucky and Indiana University ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.